A novel inflammatory pathway recruitment: Role for the kinin chemokine CXCL5

被引:67
作者
Duchene, Johan
Lecomte, Florence
Ahmed, Saleh
Cayla, Cecile
Pesquero, Joao
Bader, Michael
Perretti, Mauro
Ahluwalia, Amrita [1 ]
机构
[1] St Barts & London Med Sch, William Harvey Res Inst, London EC1M 6BQ, England
[2] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil
[3] Max Delbruck Ctr Mol Med, Berlin, Germany
基金
英国惠康基金;
关键词
D O I
10.4049/jimmunol.179.7.4849
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The kinin B-1 receptor is an inducible receptor not normally expressed but induced by inflammatory stimuli and plays a major role in neutrophil recruitment, particularly in response to the cytokine IL-1 beta. However, the exact mechanism involved in this response is unclear. The aim of this study was to dissect the molecular mechanism involved, in particular to determine whether specific ELR-CXCL chemokines (specific neutrophil chemoattractants) played a role. Using intravital microscopy, we demonstrated that IL-1 beta-induced leukocyte rolling, adherence, and emigration in mesenteric venules of wild-type (WT) mice, associated with an increase in B, receptor mRNA expression, were substantially attenuated (>80%) in B, receptor knockout mice (B1KO). This effect in B1KO mice was correlated with a selective down-regulation of IL-1 beta-induced CXCL5 mRNA and protein expression compared with WT mice. Furthermore a selective neutralizing CXCL5 Ab caused profound suppression of leukocyte emigration in IL-1 beta-treated WT mice. Finally, treatment of human endothelial cells with IL-1 beta enhanced mRNA expression of the B, receptor and the human (h) CXCL5 homologues (hCXCL5 and hCXCL6). This response was suppressed by similar to 50% when cells were pretreated with the B, receptor antagonist des-Arg(9)-[Leu(8)]-bradykinin while treatment with des-Arg(9)-bradykinin, the B-1 receptor agonist, caused a concentration-dependent increase in hCXCL5 and hCXCL6 mRNA expression. This study unveils a proinflammatory pathway centered on kinin B-1 receptor activation of CXCL5 leading to leukocyte trafficking and highlights the B-1 receptor as a potential target in the therapeutics of inflammatory disease.
引用
收藏
页码:4849 / 4856
页数:8
相关论文
共 51 条
[1]  
Ahluwalia A, 1996, J IMMUNOL, V156, P269
[2]  
Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298
[3]   Neutrophils in development of multiple organ failure in sepsis [J].
Brown, K. A. ;
Brain, S. D. ;
D Pearson, J. ;
D Edgeworth, J. ;
Lewis, S. M. ;
Treacher, D. F. .
LANCET, 2006, 368 (9530) :157-169
[4]   Validation of the anti-inflammatory properties of small molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle [J].
Catley, Matthew C. ;
Sukkar, Maria B. ;
Chung, K. Fan ;
Jaffee, Bruce ;
Liao, Sha-Mei ;
Coyle, Anthony J. ;
Haddad, El-Bdaoui ;
Barnes, Peter J. ;
Newton, Robert .
MOLECULAR PHARMACOLOGY, 2006, 70 (02) :697-705
[5]   Chemokine-cytokine cross-talk -: The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-κB pathway [J].
Chandrasekar, B ;
Melby, PC ;
Sarau, HM ;
Raveendran, M ;
Perla, RP ;
Marelli-Berg, FM ;
Dulin, NO ;
Singh, IS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (07) :4675-4686
[6]  
Chandrasekar B, 2001, CIRCULATION, V103, P2296
[7]  
Cuzzocrea S, 1997, J IMMUNOL, V159, P5089
[8]   The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1 [J].
Dinarello, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :732-734
[9]   Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation [J].
Dinarello, CA .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :378-385
[10]  
DINARELLO CA, 1993, NEW ENGL J MED, V328, P106